Impact of a drug utilization review program on high‐risk use of prescription controlled substances

  title={Impact of a drug utilization review program on high‐risk use of prescription controlled substances},
  author={Matthew Daubresse and Patrick P. Gleason and Yi Peng and Nilay D. Shah and Stephen T Ritter and G. Caleb Alexander},
  journal={Pharmacoepidemiology and Drug Safety},
Prescription drug abuse has prompted considerable concern. We evaluated a retrospective drug utilization review program to reduce controlled substance use among individuals with high‐risk utilization. 

Controlling controlled substances abuse and misuse by managed care payers: a new generation of risk management initiatives?

  • P. Coplan
  • Medicine
    Pharmacoepidemiology and drug safety
  • 2014
A letter sent to prescribers of patients with high controlled substances risk scores may be beneficial in reducing abuse or misuse of controlled substances, and the intervention design has some weaknesses that affect causal interpretation.

Effect of Nationwide Concurrent Drug Utilization Review Program on Drug-Drug Interactions and Related Health Outcome.

Implementation of a DUR program may reduce the adverse health outcomes posed by DDIs in patients on combination of benzodiazepines and enzyme inhibitors potentially QTc-prolongation agents.

Trends in opioid prescribing and co‐prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001–2010

Characterize trends in opioid prescribing and co‐prescribing of sedative hypnotics at acute and chronic musculoskeletal pain visits from 2001 to 2010.

An Experimental Test of the Effectiveness of Unsolicited Reporting by a Prescription Drug Monitoring Program in Reducing Inappropriate Acquisition of Opioids.

Requiring prescribers to solicit patients' prescription histories is likely to be a more effective use of PDMP resources than proactive notification.

Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study.

There is a linear association between increasing CS score and negative health outcomes and insurers should consider interventions to lower member CS scores.

Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group

This study suggests that PDMP unsolicited reporting to prescribers can help reduce risk measures in patients' prescription histories, which may improve health outcomes for patients receiving opioid analgesics from multiple providers.

Screening, Brief Intervention, and Referral to Treatment in a Retail Pharmacy Setting: The Pharmacist's Role in Identifying and Addressing Risk of Substance Use Disorder.

This study demonstrates the feasibility of performing Screening, Brief Intervention, and Referral to Treatment-based screenings in a retail pharmacy setting and combining these with PDMP-risk analysis to screen patients for prescription and illicit drug misuse.

Trends in Opioid Prescribing Among Hemodialysis Patients, 2007–2014

Opioid prescribing among HD patients declined between 2012 and 2014, however, HD patients continue receiving substantially more opioids than the general US population.



Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data.

A group of queries using CS-PURE were developed and empirically validated to identify patients with potential controlled substance misuse or mismanagement that would warrant further evaluation by the treating physician, a quality assurance function, or the medical director.

Analytic models to identify patients at risk for prescription opioid abuse.

Using drug and medical claims data to develop models that could assist prescription-monitoring programs, payers, and healthcare providers in evaluating patient characteristics associated with elevated risk for prescription opioid abuse is feasible.

Retrospective drug utilization review, prescribing errors, and clinical outcomes.

Given the lack of evidence for effectiveness, and suggestions from previous research of possible harm, policymakers should consider withdrawing the legislative mandate for retrospective drug utilization review.

An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients.

An integrated, pharmacy-based program to improve patients' adherence and physicians' initiation rates and was cost-effective, with a return on investment of approximately $3 for every $1 spent highlights the central role that pharmacists can play in promoting the appropriate initiation of and adherence to therapy for chronic diseases.

Case Management: Ongoing Evaluation of Patients' Needs in an Opioid Treatment Program

  • P. Abbott
  • Medicine, Psychology
    Professional case management
  • 2010
A project funded by the Centers of Substance Abuse Treatment looked at the use of case managers and specifically at the treatment needs of opioid-dependent patients, finding critical services most requested were vocational, employment, transportation, dental, emotional, and smoking cessation.

Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective.

An updated 10-year perspective on therapeutic use, abuse, and non-medical use of opioids and their consequences is provided.

The implications of therapeutic complexity on adherence to cardiovascular medications.

Medication use and prescription filling for patients with cardiovascular disease is complex, and strategies to reduce this complexity may help improve medication adherence.

The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures

The authors estimate that the drug benefit saved people about $9 a month and gave them an extra 14 days of pills, on average, using data from a random sample of pharmacy customers who were beneficiaries of the program after the enrollment deadline.